MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
multiple myeloma,lenalidomide,elranatamab,disease-positive
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要